



Datasheet for ABIN7272125

beta Amyloid Protein

4 Images



[Go to Product page](#)

Overview

| | |
|---------------|---|
| Quantity: | 100 µg |
| Target: | beta Amyloid (Abeta) |
| Origin: | Human |
| Source: | Synthetic |
| Protein Type: | Synthetic |
| Application: | Western Blotting (WB), In vitro Assay (in vitro), In vivo Studies (in vivo) |

Product Details

| | |
|-----------|---|
| Purpose: | Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated) Monomers |
| Sequence: | DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA |
| Purity: | >95% pure using mass spec and HPLC. |

Target Details

| | |
|-------------------|--|
| Target: | beta Amyloid (Abeta) |
| Alternative Name: | Amyloid Beta (Abeta Products) |
| Background: | Our amyloid beta peptide 1-42 (A β 42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH ₂ O, our A β 42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our A β 42 monomers were not toxic to primary rat cortical neurons. In the brain, |

Target Details

amyloid beta peptide (A β) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of A β plaques in the brain is considered a hallmark of Alzheimer's disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble A β oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). A β oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). A β was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of A β were shown to be associated with lower survival rates in Parkinson's disease patients with dementia (7)., cellular localisation: Cell Membrane , Intracellular Vesicles

Molecular Weight: 4.5 kDa

Gene ID: 351

UniProt: [P05067](#)

Pathways: [Inflammasome](#)

Application Details



Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Storage: -80 °C

Storage Comment: -80°C



Electron Microscopy

Image 1. AFM of amyloid beta 1-42 monomers (ABIN7272125, ABIN7272126 and ABIN7272127, left), oligomers (ABIN7272125, ABIN7272126 and ABIN7272127, middle) and fibrils (ABIN7272125, ABIN7272126 and ABIN7272127, right). Atomic force microscopy analysis of 1.0 mg/mL samples diluted to 0.1 mg/mL in dH₂O, mounted on freshly cleaved mica, washed, dried and analyzed with tapping mode. Representative images are 2.5 x 2.5 μm x-y with a z-range of 10 nm.

Western Blotting

Image 2. Western blot of amyloid beta 1-42 monomers (ABIN7272125, ABIN7272126 and ABIN7272127, left), oligomers (ABIN7272125, ABIN7272126 and ABIN7272127, middle) and fibrils (ABIN7272125, ABIN7272126 and ABIN7272127, right) using anti-amyloid beta 6E10 antibody. Amyloid beta constructs at 160 pmol were run on 4-12 % Bis-Tris SDS-PAGE, transferred to nitrocellulose in the presence of 0.02 % v/v Tween-20, and blotted with 1:1000 mouse 6E10 primary antibody (Biolegend). Oligomers observed under TEM/AFM show distinct dimer/trimer bands as well as a signal from ~37-75 kDa (middle). Fibrils observed under TEM/AFM show a signal greater than 100 kDa and a distinct signal in the stacking gel (right).




Image 3. Amyloid beta 1-42 oligomers (ABIN7272125, ABIN7272126 and ABIN7272127) and fibrils (ABIN7272125, ABIN7272126 and ABIN7272127) show a dose-dependent toxicity to primary rat cortical neurons, but not monomers (ABIN7272125, ABIN7272126 and ABIN7272127). Survival of rat primary cortical neurons 14 days after treatment with different concentrations of (A) monomers, (B) oligomers or (C) fibrils quantified by MAP2 positive neurons and

Images

expressed as a percentage of control. Fibrils and respective vehicle controls were initially sonicated in a Bioruptor. Test conditions were run in the same plate as untreated control and vehicle controls, which consisted of buffer without amyloid beta 1-42 protein. Data expressed as mean +/- s.e.m. (n=6). A global analysis of the data was performed using a one-way ANOVA followed by Dunnett's test, ** p<0.01 stats vs control, ## p<0.01, ##### p<0.0001 stats vs vehicle control. represents untreated control condition.

Please check the [product details page](#) for more images. Overall 4 images are available for ABIN7272125.